~~<i id='5220086E37'><strike id='5220086E37'><tt id='5220086E37'><pre id='5220086E37'></pre></tt></strike></i>~~

Home» explore» entertainment

entertainment

author：fashion 2025-08-24 00:08:48 Page View：96

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Affordable Connectivity Program vital to health care, experts say
Next article： Heart attack and stroke risk calculators need revising

focus

Malaria cases in Florida and Texas: Here’s what you need to know

MosquitoscaughtfortestingawaitshipmenttoalabinMcAllen,Texas,inApril2016tobetestedformosquito-bornedi

Some medical students still think black patients feel less pain

APStockBlackpatientsaresystematicallyundertreatedforpain,decadesofresearchhaveshown.Andastudypublish

How to save PrEP access — and even expand it

UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

Decentralized clinical trials need collaboration to achieve wider use

AdobeDespitegroundbreakingadvancesinbasicandclinicalscienceandtechnology,clinicaltrialmethodshavenot